60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

60 Degrees Pharma has successfully achieved the necessary enrollment for the interim analysis of its hospitalized babesiosis trial. The data from the analysis is anticipated to be available by October 6, 2026.